Aprea Therapeutics, Inc. (APRE): Cash & Equivalents
$14.60M
As of 2025-12-31
$41.23M
As of 2026-06-30
-20.3%
3-year compound annual growth
-30.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.60M | -36.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $22.85M | +5.8% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $21.61M | -24.9% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $28.79M | -45.8% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $53.08M | -40.4% | 2024-03-26, Balance as of period end |
| 2020-12-31 | $89.02M | -31.6% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $130.09M | +98.1% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $65.68M | n/a | 2020-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $14.60M | -36.1% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $14.44M | +7.1% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $1.24M | -2.1% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $14.67M | -22.2% |
| Aditxt, Inc. (ADTX) | 2024-12-31 | $833.0K | +757.9% |
| Cingulate Inc. (CING) | 2025-12-31 | $10.95M | -10.3% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $7.71M | -74.5% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $5.21M | -16.1% |
Compare APRE, RVPH, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗